AUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix® and Zircaix®
Join Telix this week at the 2025 The American Urological Association (AUA) Annual Meeting in Las Vegas,…
Read moreNews & Views
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Telix announces its Annual General Meeting of shareholders to be held…
Read more
Notice of Annual General Meeting 2025
Telix announces its Annual General Meeting of shareholders to be held…
Read more
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Telix today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1…
Read more
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden
News,
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Swedish MPA for the…
Read more
Telix Announces Cardinal Health for Gozellix Commercial Distribution
News,
Telix today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for…
Read more
Telix Responds to Recent U.S. Government Actions
Telix advises that it does not expect any material impact on its business or supply chain as the result of the international trade tariffs levied by the U.S. government, announced…
Read more
Telix Appoints Paul Schaffer as Chief Technology Officer
News,
Telix today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today….
Read more
Anne Whitaker Appointed as Non-Executive Director
Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April…
Read more
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
Telix today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the…
Read more